Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Clinton Yam,Miral Patel,Holly A Hill,Ryan Sun,Roland L Bassett Jr,Elisabeth Kong,Senthil Damodaran,Kimberly B Koenig,Sausan Abouharb,Sadia Saleem,Ajit K Bisen,Rashmi K Murthy,David L Ramirez,Gaiane M Rauch,Beatriz E Adrada,Rosalind P Candelaria,Xiaoping Wang,Elizabeth A Mittendorf,Alastair M Thompson,Jason B White,Elizabeth E Ravenberg,Alyson R Clayborn,Qing-Qing Ding,Daniel J Booser,Oluchi Oke,Abenaa M Brewster,Gabriel N Hortobagyi,Nuhad K Ibrahim,Jennifer K Litton,Vicente Valero,Banu K Arun,Debu Tripathy,Jeffrey T Chang,Ken Chen,Anil Korkut,Stacy L Moulder,Lei Huo,Bora Lim,Naoto T Ueno
DOI: https://doi.org/10.1158/2767-9764.CRC-24-0255
2024-10-01
Abstract:Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)-resistant TNBC (NCT02593175). Patients and methods: Patients with early-stage, AC-resistant TNBC, defined as disease progression or ≤80% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available. Results: From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed. Conclusions: This study met its primary endpoint (pCR/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial. Significance: The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.